The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Participants will undergo two positron emission tomography (PET) scans, one \[11C\]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one \[18F\]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan. The main question\[s\] it aims to answer are: 1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP. 2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP
Study Type
OBSERVATIONAL
Enrollment
90
One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)
One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)
One MRI scan
Centre for Addiction and Mental Health
Toronto, Ontario, Canada
RECRUITINGVesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND)
The investigators will determine if VMAT2 BPND is changed in ventral striatum and dorsal putamen in COVID-DNP.
Time frame: within 3 to 4 weeks after initiation of screening
Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT)
The investigators will determine if SV2A VT is changed in ventral striatum and dorsal putamen in COVID-DNP
Time frame: within 3 to 4 weeks after initiation of screening
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.